Datroway, an antibody-drug conjugate, becomes the first therapy to show an overall survival benefit versus chemotherapy in metastatic triple-negative breast cancer patients ineligible for immunotherapy.
Datroway, an antibody-drug conjugate, becomes the first therapy to show an overall survival benefit versus chemotherapy in metastatic triple-negative breast cancer patients ineligible for immunotherapy.